<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02784899</url>
  </required_header>
  <id_info>
    <org_study_id>4-2015-0706</org_study_id>
    <nct_id>NCT02784899</nct_id>
  </id_info>
  <brief_title>Effect of Iloprost on Pulmonary Oxygenation in Patients With Low Diffusing Capacity During One-lung Ventilation</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      One lung ventilation (OLV) is essential during thoracic surgery. During OLV, intrapulmonary&#xD;
      shunt can be increased resulting hypoxemia. Although OLV technique had been advanced so far,&#xD;
      hypoxemia during OLV reaches about 10% in spite of inspired oxygen fraction 100%. Iloprost is&#xD;
      a prostaglandin analogue used for pulmonary hypertension, which can decrease pulmonary artery&#xD;
      resistance by selectively dilating pulmonary artery. In this prospective, randomized, double&#xD;
      blind study, investigators are planning to investigate the effects of iloprost on respiratory&#xD;
      physiology (intrapulmonary shunt, deadspace, oxygenation, etc).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 8, 2015</start_date>
  <completion_date type="Actual">June 30, 2017</completion_date>
  <primary_completion_date type="Actual">June 30, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PaO2(partial pressure of arterial oxygen) ratio</measure>
    <time_frame>40 minutes after iloprost inhalation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>incidence of intrapulmonary shunt</measure>
    <time_frame>40 minutes after iloprost inhalation</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>iloprost group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>iloprost inhalation group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>normal saline inhalation group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>iloprost</intervention_name>
    <description>20μg(2ml) of inhaled iloprost (Ventavis®)&#xD;
When anesthesia induction finishes, change patients' position from supine to lateral position and measure arterial blood gas analysis (ABGA), venous blood gas analysis (VBGA) while two lung is ventilated. After 20 minutes of applying one lung ventilation, measure ABGA. Apply iloprost or normal saline inhalation for each iloprost and control group and measure ABGA at the time of 20 min and 40 min after iloprost (or normal saline) inhalation has finished.</description>
    <arm_group_label>iloprost group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>normal saline</intervention_name>
    <description>20μg(2ml) of inhaled normal saline&#xD;
When anesthesia induction finishes, change patients' position from supine to lateral position and measure ABGA, VBGA while two lung is ventilated. After 20 minutes of applying one lung ventilation, measure ABGA. Apply iloprost or normal saline inhalation for each iloprost and control group and measure ABGA at the time of 20 min and 40 min after iloprost (or normal saline) inhalation has finished.</description>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  scheduled for Video-assisted thoracoscopic surgery (VATS) lobectomy&#xD;
&#xD;
          -  40 &lt; age &lt; 80&#xD;
&#xD;
          -  American Society of Anaesthesiologists (ASA) physical status classification I~III&#xD;
&#xD;
          -  diffusing capacity (DLCO) &lt;75% at pre op. pulmonary function test&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  American Society of Anaesthesiologists (ASA) physical status classification IV&#xD;
&#xD;
          -  New York Heart Association (NYHA) class III~IV&#xD;
&#xD;
          -  Severe obstructive lung disease and/or restrictive lung disease patients&#xD;
&#xD;
          -  patients with end-organ diseases (i.e. heart failure, respiratory failure, hepatic&#xD;
             failure, renal failure)&#xD;
&#xD;
          -  arrhythmia&#xD;
&#xD;
          -  pregnant women&#xD;
&#xD;
          -  disease that can influence the DLCO result (anemia, pulmonary vascular disease)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Anaesthesiology and Pain Medicine, Anaesthesia and Pain Research Institute, Yonsei University College of Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>May 16, 2016</study_first_submitted>
  <study_first_submitted_qc>May 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2016</study_first_posted>
  <last_update_submitted>June 19, 2018</last_update_submitted>
  <last_update_submitted_qc>June 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iloprost</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

